Cargando…

Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses

The present work aimed to explain the differences in oral performance in fasted humans who were categorized into groups based on the three different drug product formulations of dexketoprofen trometamol (DKT) salt—Using a combination of in vitro techniques and pharmacokinetic analysis. The non-bioeq...

Descripción completa

Detalles Bibliográficos
Autores principales: Bermejo, Marival, Kuminek, Gislaine, Al-Gousous, Jozef, Ruiz-Picazo, Alejandro, Tsume, Yasuhiro, Garcia-Arieta, Alfredo, González-Alvarez, Isabel, Hens, Bart, Mudie, Deanna, Amidon, Gregory E., Rodriguez-Hornedo, Nair, Amidon, Gordon L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471271/
https://www.ncbi.nlm.nih.gov/pubmed/30884755
http://dx.doi.org/10.3390/pharmaceutics11030122
_version_ 1783411990471901184
author Bermejo, Marival
Kuminek, Gislaine
Al-Gousous, Jozef
Ruiz-Picazo, Alejandro
Tsume, Yasuhiro
Garcia-Arieta, Alfredo
González-Alvarez, Isabel
Hens, Bart
Mudie, Deanna
Amidon, Gregory E.
Rodriguez-Hornedo, Nair
Amidon, Gordon L.
author_facet Bermejo, Marival
Kuminek, Gislaine
Al-Gousous, Jozef
Ruiz-Picazo, Alejandro
Tsume, Yasuhiro
Garcia-Arieta, Alfredo
González-Alvarez, Isabel
Hens, Bart
Mudie, Deanna
Amidon, Gregory E.
Rodriguez-Hornedo, Nair
Amidon, Gordon L.
author_sort Bermejo, Marival
collection PubMed
description The present work aimed to explain the differences in oral performance in fasted humans who were categorized into groups based on the three different drug product formulations of dexketoprofen trometamol (DKT) salt—Using a combination of in vitro techniques and pharmacokinetic analysis. The non-bioequivalence (non-BE) tablet group achieved higher plasma C(max) and area under the curve (AUC) than the reference and BE tablets groups, with only one difference in tablet composition, which was the presence of calcium monohydrogen phosphate, an alkalinizing excipient, in the tablet core of the non-BE formulation. Concentration profiles determined using a gastrointestinal simulator (GIS) apparatus designed with 0.01 N hydrochloric acid and 34 mM sodium chloride as the gastric medium and fasted state simulated intestinal fluids (FaSSIF-v1) as the intestinal medium showed a faster rate and a higher extent of dissolution of the non-BE product compared to the BE and reference products. These in vitro profiles mirrored the fraction doses absorbed in vivo obtained from deconvoluted plasma concentration–time profiles. However, when sodium chloride was not included in the gastric medium and phosphate buffer without bile salts and phospholipids were used as the intestinal medium, the three products exhibited nearly identical concentration profiles. Microscopic examination of DKT salt dissolution in the gastric medium containing sodium chloride identified that when calcium phosphate was present, the DKT dissolved without conversion to the less soluble free acid, which was consistent with the higher drug exposure of the non-BE formulation. In the absence of calcium phosphate, however, dexketoprofen trometamol salt dissolution began with a nano-phase formation that grew to a liquid–liquid phase separation (LLPS) and formed the less soluble free acid crystals. This phenomenon was dependent on the salt/excipient concentrations and the presence of free acid crystals in the salt phase. This work demonstrated the importance of excipients and purity of salt phase on the evolution and rate of salt disproportionation pathways. Moreover, the presented data clearly showed the usefulness of the GIS apparatus as a discriminating tool that could highlight the differences in formulation behavior when utilizing physiologically-relevant media and experimental conditions in combination with microscopy imaging.
format Online
Article
Text
id pubmed-6471271
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64712712019-04-27 Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses Bermejo, Marival Kuminek, Gislaine Al-Gousous, Jozef Ruiz-Picazo, Alejandro Tsume, Yasuhiro Garcia-Arieta, Alfredo González-Alvarez, Isabel Hens, Bart Mudie, Deanna Amidon, Gregory E. Rodriguez-Hornedo, Nair Amidon, Gordon L. Pharmaceutics Article The present work aimed to explain the differences in oral performance in fasted humans who were categorized into groups based on the three different drug product formulations of dexketoprofen trometamol (DKT) salt—Using a combination of in vitro techniques and pharmacokinetic analysis. The non-bioequivalence (non-BE) tablet group achieved higher plasma C(max) and area under the curve (AUC) than the reference and BE tablets groups, with only one difference in tablet composition, which was the presence of calcium monohydrogen phosphate, an alkalinizing excipient, in the tablet core of the non-BE formulation. Concentration profiles determined using a gastrointestinal simulator (GIS) apparatus designed with 0.01 N hydrochloric acid and 34 mM sodium chloride as the gastric medium and fasted state simulated intestinal fluids (FaSSIF-v1) as the intestinal medium showed a faster rate and a higher extent of dissolution of the non-BE product compared to the BE and reference products. These in vitro profiles mirrored the fraction doses absorbed in vivo obtained from deconvoluted plasma concentration–time profiles. However, when sodium chloride was not included in the gastric medium and phosphate buffer without bile salts and phospholipids were used as the intestinal medium, the three products exhibited nearly identical concentration profiles. Microscopic examination of DKT salt dissolution in the gastric medium containing sodium chloride identified that when calcium phosphate was present, the DKT dissolved without conversion to the less soluble free acid, which was consistent with the higher drug exposure of the non-BE formulation. In the absence of calcium phosphate, however, dexketoprofen trometamol salt dissolution began with a nano-phase formation that grew to a liquid–liquid phase separation (LLPS) and formed the less soluble free acid crystals. This phenomenon was dependent on the salt/excipient concentrations and the presence of free acid crystals in the salt phase. This work demonstrated the importance of excipients and purity of salt phase on the evolution and rate of salt disproportionation pathways. Moreover, the presented data clearly showed the usefulness of the GIS apparatus as a discriminating tool that could highlight the differences in formulation behavior when utilizing physiologically-relevant media and experimental conditions in combination with microscopy imaging. MDPI 2019-03-15 /pmc/articles/PMC6471271/ /pubmed/30884755 http://dx.doi.org/10.3390/pharmaceutics11030122 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bermejo, Marival
Kuminek, Gislaine
Al-Gousous, Jozef
Ruiz-Picazo, Alejandro
Tsume, Yasuhiro
Garcia-Arieta, Alfredo
González-Alvarez, Isabel
Hens, Bart
Mudie, Deanna
Amidon, Gregory E.
Rodriguez-Hornedo, Nair
Amidon, Gordon L.
Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses
title Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses
title_full Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses
title_fullStr Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses
title_full_unstemmed Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses
title_short Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses
title_sort exploring bioequivalence of dexketoprofen trometamol drug products with the gastrointestinal simulator (gis) and precipitation pathways analyses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471271/
https://www.ncbi.nlm.nih.gov/pubmed/30884755
http://dx.doi.org/10.3390/pharmaceutics11030122
work_keys_str_mv AT bermejomarival exploringbioequivalenceofdexketoprofentrometamoldrugproductswiththegastrointestinalsimulatorgisandprecipitationpathwaysanalyses
AT kuminekgislaine exploringbioequivalenceofdexketoprofentrometamoldrugproductswiththegastrointestinalsimulatorgisandprecipitationpathwaysanalyses
AT algousousjozef exploringbioequivalenceofdexketoprofentrometamoldrugproductswiththegastrointestinalsimulatorgisandprecipitationpathwaysanalyses
AT ruizpicazoalejandro exploringbioequivalenceofdexketoprofentrometamoldrugproductswiththegastrointestinalsimulatorgisandprecipitationpathwaysanalyses
AT tsumeyasuhiro exploringbioequivalenceofdexketoprofentrometamoldrugproductswiththegastrointestinalsimulatorgisandprecipitationpathwaysanalyses
AT garciaarietaalfredo exploringbioequivalenceofdexketoprofentrometamoldrugproductswiththegastrointestinalsimulatorgisandprecipitationpathwaysanalyses
AT gonzalezalvarezisabel exploringbioequivalenceofdexketoprofentrometamoldrugproductswiththegastrointestinalsimulatorgisandprecipitationpathwaysanalyses
AT hensbart exploringbioequivalenceofdexketoprofentrometamoldrugproductswiththegastrointestinalsimulatorgisandprecipitationpathwaysanalyses
AT mudiedeanna exploringbioequivalenceofdexketoprofentrometamoldrugproductswiththegastrointestinalsimulatorgisandprecipitationpathwaysanalyses
AT amidongregorye exploringbioequivalenceofdexketoprofentrometamoldrugproductswiththegastrointestinalsimulatorgisandprecipitationpathwaysanalyses
AT rodriguezhornedonair exploringbioequivalenceofdexketoprofentrometamoldrugproductswiththegastrointestinalsimulatorgisandprecipitationpathwaysanalyses
AT amidongordonl exploringbioequivalenceofdexketoprofentrometamoldrugproductswiththegastrointestinalsimulatorgisandprecipitationpathwaysanalyses